{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:13:29Z","timestamp":1790655209750,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"nerviano"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00280-017-3303-z","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T04:13:54Z","timestamp":1492575234000},"page":"1257-1265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-9161","authenticated-orcid":false,"given":"Sandrine","family":"Aspeslagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwar","family":"Shailubhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rastilav","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"3303_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol 13:417\u2013430. doi:\n                        10.1038\/nrclinonc.2016.26","journal-title":"Nat Rev Clin Oncol"},{"key":"3303_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P (2017) Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17:93\u2013115. doi:\n                        10.1038\/nrc.2016.138","journal-title":"Nat Rev Cancer"},{"key":"3303_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","volume":"169","author":"A Nakagawara","year":"2001","unstructured":"Nakagawara A (2001) Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169:107\u2013114. doi:\n                        10.1016\/S0304-3835(01)00530-4","journal-title":"Cancer Lett"},{"key":"3303_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/esmoopen-2015-000023","volume":"1","author":"A Amatu","year":"2016","unstructured":"Amatu A, Sartore-Bianchi A, Siena S (2016) NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1:1\u201310. doi:\n                        10.1136\/esmoopen-2015-000023","journal-title":"ESMO Open"},{"key":"3303_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","volume":"15","author":"E Ardini","year":"2016","unstructured":"Ardini E, Menichincheri M, Banfi P et al (2016) Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 15:628\u2013639. doi:\n                        10.1158\/1535-7163.MCT-15-0758","journal-title":"Mol Cancer Ther"},{"key":"3303_CR6","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-10-0190","volume":"9","author":"C Albanese","year":"2010","unstructured":"Albanese C, Alzani R, Amboldi N et al (2010) Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther 9:2243\u20132254. doi:\n                        10.1158\/1535-7163.MCT-10-0190","journal-title":"Mol Cancer Ther"},{"key":"3303_CR7","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1007\/s10637-011-9774-6","volume":"30","author":"GJ Weiss","year":"2012","unstructured":"Weiss GJ, Hidalgo M, Borad MJ et al (2012) Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs 30:2334\u20132343. doi:\n                        10.1007\/s10637-011-9774-6","journal-title":"Invest New Drugs"},{"key":"3303_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000058524","volume":"60","author":"M Spielmann","year":"2001","unstructured":"Spielmann M, Llombart-Cussac A, Kalla S et al (2001) Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60:303\u2013307. doi:\n                        10.1159\/000058524","journal-title":"Oncology"},{"key":"3303_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/jco.1997.15.1.310","volume":"15","author":"FV Fossella","year":"1997","unstructured":"Fossella FV, Lippman SM, Shin DM et al (1997) Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15:310\u2013316. doi:\n                        10.1200\/jco.1997.15.1.310","journal-title":"J Clin Oncol"},{"key":"3303_CR10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1008315723253","volume":"10","author":"D Mavroudis","year":"1999","unstructured":"Mavroudis D, Malamos N, Alexopoulos A et al (1999) Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol Off J Eur Soc Med Oncol 10:211\u2013215","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3303_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2004.10.011","volume":"96","author":"MF Kose","year":"2005","unstructured":"Kose MF, Sufliarsky J, Beslija S et al (2005) A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol Oncol 96:374\u2013380. doi:\n                        10.1016\/j.ygyno.2004.10.011","journal-title":"Gynecol Oncol"},{"key":"3303_CR12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1023\/A:1008276507236","volume":"9","author":"D Castellano","year":"1998","unstructured":"Castellano D, Lianes P, Paz-Ares L et al (1998) A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol 9:457\u2013459","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3303_CR13","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Maase von der","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602\u20134608. doi:\n                        10.1200\/JCO.2005.07.757","journal-title":"J Clin Oncol"},{"key":"3303_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1124\/mol.105.012716","volume":"68","author":"LM Karnitz","year":"2005","unstructured":"Karnitz LM, Flatten KS, Wagner JM et al (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636\u20131644. doi:\n                        10.1124\/mol.105.012716","journal-title":"Mol Pharmacol"},{"key":"3303_CR15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/cc.6.1.3699","volume":"6","author":"DJ Matthews","year":"2007","unstructured":"Matthews DJ, Yakes FM, Chen J et al (2007) Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6:104\u2013110","journal-title":"Cell Cycle"},{"key":"3303_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1535-7163.MCT-08-0662","volume":"8","author":"LA Parsels","year":"2009","unstructured":"Parsels LA, Morgan MA, Tanska DM et al (2009) Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8:45\u201354. doi:\n                        10.1158\/1535-7163.MCT-08-0662","journal-title":"Mol Cancer Ther"},{"key":"3303_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/jnci\/92.3.205","volume":"87","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck S, Eisenhauer E et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 87:881\u2013886. doi:\n                        10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"key":"3303_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5009\/gnl.2014.8.1.109","volume":"8","author":"HW Lee","year":"2014","unstructured":"Lee HW, Chung MJ, Kang H et al (2014) Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Gut Liver 8:109\u2013112. doi:\n                        10.5009\/gnl.2014.8.1.109","journal-title":"Gut Liver"},{"key":"3303_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","volume":"8","author":"M Zupancic","year":"2007","unstructured":"Zupancic M, Shah PC, Shah-Khan F, Nagendra S (2007) Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 8:634\u2013641. doi:\n                        10.1016\/S1470-2045(07)70203-6","journal-title":"Lancet Oncol"},{"key":"3303_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/01.COC.0000071382.14174.C5","volume":"27","author":"S Delaloge","year":"2004","unstructured":"Delaloge S, Llombart A, Di Palma M et al (2004) Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study. Am J Clin Oncol 27:289\u2013293. doi:\n                        10.1097\/01.COC.0000071382.14174.C5","journal-title":"Am J Clin Oncol"},{"key":"3303_CR21","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1021\/jm9006559","volume":"52","author":"MG Brasca","year":"2009","unstructured":"Brasca MG, Amboldi N, Ballinari D et al (2009) Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 52:5152\u20135163. doi:\n                        10.1021\/jm9006559","journal-title":"J Med Chem"},{"key":"3303_CR22","first-page":"5s","volume":"32","author":"B Besse","year":"2014","unstructured":"Besse B, Garassino MC, Rajan A et al (2014) A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). J Clin Oncol 32:5s (suppl; abstr 7526)","journal-title":"J Clin Oncol"},{"key":"3303_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr CJ, Beach D, Shapiro GI (2016) Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 6:353\u2013367. doi:\n                        10.1158\/2159-8290.CD-15-0894","journal-title":"Cancer Discov"},{"key":"3303_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153\u2013166. doi:\n                        10.1038\/nrc2602","journal-title":"Nat Rev Cancer"},{"key":"3303_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/10409239609106585","volume":"31","author":"A Sidle","year":"1996","unstructured":"Sidle A, Palaty C, Dirks P et al (1996) Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol 31:237\u2013271. doi:\n                        10.3109\/10409239609106585","journal-title":"Crit Rev Biochem Mol Biol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3303-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T05:52:05Z","timestamp":1495259525000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3303-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3303"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3303-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}